Rubinstein-Taybi syndrome and psychiatric disorders.

Irvin et al. (1998) looked at 13 people with Rubinstein-Taybi syndrome. They asked what mental-health labels these people carried and how they reacted to antipsychotic drugs.

The team wrote down each patient’s mood, tics, or OCD-type habits. They also noted any bad reactions to neuroleptic pills.

Several patients had mood swings, tics, or obsessive thoughts packed together. Most became very sensitive to normal doses of antipsychotics, showing stiff muscles or big drops in alertness.

The authors think the chromosome spot tied to RTS, 16p13.3, may also set up this drug risk.

Galéra et al. (2009) later compared RTS kids to matched peers and saw no extra anxiety or acting-out. This seems to clash with the 1998 report, but the 2009 group was younger and used rating scales, not clinic charts. The two studies together say: watch for mood-tic clusters in adults, not every child.

Case-Smith et al. (2015) zoomed in on repetitive behaviors and found a unique pattern separate from autism. Their survey backs the 1998 idea of an OCD-tic flavor, yet shows it can live without full social-communication delay.

Giani et al. (2022) tracked RTS across age and showed anxiety rises as kids grow. This extends the 1998 adult snapshot: the psychiatric risk may start low and climb, so screen again at each birthday.

Before you order risperidone or haloperidol for any RTS client, pause. Ask about past drug reactions and start at half the usual dose. Track mood, tics, and anxiety yearly, not just at intake. Share the drug-sensitivity note with prescribers so they can pick safer choices or behavior plans first.